Biosimilars Market Research Report by Indication (Autoimmune Diseases, Blood Disorders, and Chronic Diseases), by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides), by Manufacturing, by Region (Am

Biosimilars Market Research Report by Indication (Autoimmune Diseases, Blood Disorders, and Chronic Diseases), by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides), by Manufacturing, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

The Global Biosimilars Market size was estimated at USD 9.75 billion in 2020 and expected to reach USD 12.06 billion in 2021, at a CAGR 24.10% to reach USD 35.62 billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Indication, the market was studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.

Based on Product, the market was studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.

Based on Manufacturing, the market was studied across Contract Manufacturing and In-House Manufacturing.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market, including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?
6. What is the market share of the leading vendors in the Global Biosimilars Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilars Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Growing pressure to reduce healthcare expenditure
5.2.2. Growing demands of pharmaceutical drugs
5.2.3. Expiration of major patents during the forecast period
5.2.4. Supportive government initiative and awareness creating programs in the developing economies
5.2.5. Lower cost biosimilars drugs than original biologics
5.3. Restraints
5.3.1. Reluctance of physicians to prescribe biosimilars
5.3.2. Unawareness among patients and preference for brand
5.4. Opportunities
5.4.1. New indications and patent expiry of biologic products
5.4.2. Potential in emerging markets
5.4.3. Emergence of bio-betters drugs
5.5. Challenges
5.5.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.5.2. High investment required for research and development
6. Biosimilars Market, by Indication
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology
7. Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon
8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AMEGA Biotech S.A.
13.2. Amgen Inc.
13.3. Apotex Inc.
13.4. Biosidus S.A.
13.5. Bioton S.A.
13.6. Innovent Biologics, Inc.
13.7. JHL Biotech, Inc.
13.8. LG Chem, Ltd.
13.9. Merck Sharp & Dohme Corp.
13.10. Mylan N.V.
13.11. Pfizer Inc.
13.12. Sandoz International GmbH
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL BIOSIMILARS MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 3. GLOBAL BIOSIMILARS MARKET: MARKET DYNAMICS
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2026
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2026 (USD BILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2018-2026 (USD BILLION)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2026 (USD BILLION)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2026 (USD BILLION)
FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2026 (USD BILLION)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (%)
FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (USD BILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2026
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2026 (USD BILLION)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2026 (USD BILLION)
FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2018-2026 (USD BILLION)
FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2026 (USD BILLION)
FIGURE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2018-2026 (USD BILLION)
FIGURE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2018-2026 (USD BILLION)
FIGURE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2018-2026 (USD BILLION)
FIGURE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2026 (USD BILLION)
FIGURE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2018-2026 (USD BILLION)
FIGURE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2018-2026 (USD BILLION)
FIGURE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2026 (USD BILLION)
FIGURE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2018-2026 (USD BILLION)
FIGURE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2018-2026 (USD BILLION)
FIGURE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2018-2026 (USD BILLION)
FIGURE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2026 (USD BILLION)
FIGURE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2018-2026 (USD BILLION)
FIGURE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2018-2026 (USD BILLION)
FIGURE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 56. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2026 (%)
FIGURE 57. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2026 (USD BILLION)
FIGURE 58. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2026
FIGURE 59. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2026 (USD BILLION)
FIGURE 60. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 61. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2026 (USD BILLION)
FIGURE 62. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 63. AMERICAS BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 64. ARGENTINA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 65. BRAZIL BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 66. CANADA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 67. MEXICO BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 68. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 69. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 70. AUSTRALIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 71. CHINA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 72. INDIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 73. INDONESIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 74. JAPAN BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 75. MALAYSIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 76. PHILIPPINES BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 77. SINGAPORE BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 78. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 79. TAIWAN BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 80. THAILAND BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 81. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 82. FRANCE BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 83. GERMANY BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 84. ITALY BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 85. NETHERLANDS BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 86. QATAR BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 87. RUSSIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 88. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 89. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 90. SPAIN BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 91. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 92. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 93. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX
FIGURE 94. GLOBAL BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 95. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILARS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL BIOSIMILARS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2026 (USD BILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2026 (USD BILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2026 (USD BILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2026 (USD BILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2026 (USD BILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2026 (USD BILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2026 (USD BILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2026 (USD BILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2026 (USD BILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2026 (USD BILLION)
TABLE 32. AMERICAS BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 33. ARGENTINA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 34. BRAZIL BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 35. CANADA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 36. MEXICO BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 37. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 38. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 39. AUSTRALIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 40. CHINA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 41. INDIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 42. INDONESIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 43. JAPAN BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 44. MALAYSIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 45. PHILIPPINES BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 46. SINGAPORE BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 47. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 48. TAIWAN BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 49. THAILAND BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 51. FRANCE BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 52. GERMANY BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 53. ITALY BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 54. NETHERLANDS BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 55. QATAR BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 56. RUSSIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 57. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 58. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 59. SPAIN BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 60. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 61. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 62. GLOBAL BIOSIMILARS MARKET: SCORES
TABLE 63. GLOBAL BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 64. GLOBAL BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 65. GLOBAL BIOSIMILARS MARKET: RANKING
TABLE 66. GLOBAL BIOSIMILARS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 67. GLOBAL BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 68. GLOBAL BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 69. GLOBAL BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 70. GLOBAL BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 71. GLOBAL BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 72. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook